673 Results for "

K-Ras

" in MedChemExpress (MCE) Product Catalog:
Products (673)

673 Results for "K-Ras" in MCE Product Catalog:

Cat. No.: HY-148278
CAS No.: 2750570-55-7
Purity:  99.83%
Target:  

SOS1 Ras

Research Areas:  

Cancer

BI-0474 is a potent KRAS G12C inhibitor with an IC50 value of 7.0 nM for the GDP-KRAS::SOS1 protein-protein interaction. BI-0474 exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation. BI-0474 also shows good anti-tumour activity in non-small cell lung cancer xenograft models .
loading...
    loading...
Cat. No.: HY-161233
Target:  

PROTACs SOS1 ERK p38 MAPK

Research Areas:  

Cancer

BTX-6654 is a SOS1 PROTAC degrader. BTX-6654 induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 can be used in research on various cancers driven by KRAS mutations .
loading...
    loading...
Cat. No.: HY-161233A
Target:  

PROTACs SOS1 ERK p38 MAPK

Research Areas:  

Cancer

BTX-6654 formate is a SOS1 PROTAC degrader. BTX-6654 formate induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 formate can be used in research on various cancers driven by KRAS mutations .
loading...
    loading...
Cat. No.: HY-164492
CAS No.: 1455031-68-1
Target:  

Raf

Research Areas:  

Cancer

LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .
loading...
    loading...
Cat. No.: HY-115907A
CAS No.: 2915618-92-5
Target:  

Drug Isomer

Research Areas:  

Cancer

(rac)-K20 is the racemate of K20, a KRas G12C inhibitor with an IC50 of 1.16 μM. K20 has antitumor activity .
loading...
    loading...
Cat. No.: HY-152848
CAS No.: 2641747-54-6
Purity:  99.60%
Synonyms: IBI351; GFH925
Target:  

Ras

Research Areas:  

Cancer

Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .
loading...
    loading...
Cat. No.: HY-154959
CAS No.: 2489226-14-2
Purity:  99.81%
Target:  

Ras

Research Areas:  

Cancer

AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase KRAS G12C inhibitor. AZD4747 has the potential to study cancer .
loading...
    loading...
Cat. No.: HY-114277B
CAS No.: 2296729-66-1
Purity:  99.09%
Synonyms: AMG-510 isomer
Target:  

Ras

Research Areas:  

Others

Sotorasib (AMG-510) isomer is the less active isomer of Sotorasib (AMG-510). AMG-510 is a potent KRAS G12C covalent inhibitor.
loading...
    loading...
Cat. No.: HY-145737A
Purity:  99.38%
Target:  

PROTACs SOS1 Ras PERK

Research Areas:  

Cancer

PROTAC SOS1 degrader-1 TFA is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 TFA induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 TFA reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 TFA inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 TFA can be used for the research of KRAS-driven cancers .
loading...
    loading...
Cat. No.: HY-W1126235
CAS No.: 2253733-45-6
Synonyms: D223
Research Areas:  

Metabolic Disease

DS02312223 (D223) is a molecular glue that promotes the binding of RAS to PI3Kα, with a Kd of 0.76 μM for p110α. DS02312223 increases the binding affinity between GTP-bound KRAS (KRAS-GMPPNP) and p110α by nearly three orders of magnitude (KD = 0.017 μM). DS02312223 stimulates the translocation of GLUT4 to the plasma membrane. DS02312223 promotes glucose uptake in the absence of insulin. DS02312223 can be used in diabetes research .
loading...
    loading...
Cat. No.: HY-155356A
CAS No.: 3053689-54-3
Target:  

PROTACs Ras PERK Akt Caspase

Research Areas:  

Cancer

YN14 mixture of diastereomers is a diastereomer mixture of YN14 (HY-155356). YN14 is a KRAS G12C PROTAC degrader that recruits E3 ubiquitin ligase to induce the polyubiquitination and proteasomal degradation of KRAS G12C. YN14 induces tumor cell apoptosis, cell cycle arrest, and cell migration inhibition. YN14 exhibits in vivo antitumor proliferative activity in tumor cell xenograft nude mice. YN14 can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-161450
Target:  

PROTACs SOS1 ERK

Research Areas:  

Cancer

LHF418 is a SOS1 PROTAC degrader that induces the degradation of the target protein SOS1 by recruiting cereblon. LHF418 promotes the formation of the SOS1-PROTAC-CRBN ternary complex and induces SOS1 degradation in a cereblon- and proteasome-dependent manner. LHF418 inhibits EGF-induced ERK1/2 phosphorylation and the clonogenic growth of KRAS-mutant cancer cells. LHF418 can be used in studies related to SOS1-targeted protein degradation and KRAS-driven tumors .
loading...
    loading...
Cat. No.: HY-181420A
CAS No.: 3029443-36-2
Research Areas:  

Cancer

BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-163939
CAS No.: 2794934-49-7
Target:  

SOS1 Ras

Research Areas:  

Cancer

RGT-018 is a potent and orally active SOS1 inhibitor with anti-tumor effects. RGT-018 exerts anti-cancer cell proliferation activity by inhibiting KRAS activation .
loading...
    loading...
Cat. No.: HY-176491
Target:  

PROTAC Linkers

Alkyne-pyrazine-O-piperidine-(1-methylcyclopropyl) methanol is a PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC pan-KRAS degrader-1 (HY-176489) .
loading...
    loading...
Cat. No.: HY-144213
CAS No.: 2758690-15-0
Target:  

SOS1 Ras

Research Areas:  

Cancer

SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8) .
loading...
    loading...
Cat. No.: HY-153262
CAS No.: 2706637-12-7
Synonyms: (7R)-D3S-001
Target:  

Ras

Research Areas:  

Cancer

KRASG12C IN-2 (compound 17) is an orally active KRAS G12C inhibitor. KRASG12C IN-2 inhibits tumor growth in mice .
loading...
    loading...
Cat. No.: HY-162249
Target:  

Ras

Research Areas:  

Cancer

ASP6918 is a potent and orally active KRAS G12C inhibitor with an IC50 value of 0.028 µM. ASP6918 inhibits cell growth. ASP6918 shows antitumor activity .
loading...
    loading...
Cat. No.: HY-162321
CAS No.: 1286482-29-8
Target:  

Ras

Research Areas:  

Cancer

ZINC57632462 (ACA-6) is a non-covalent allosteric KRAS inhibitor. ZINC57632462 disrupts nucleotide exchange and inhibits RAS-effector interaction. ZINC57632462 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-104067
CAS No.: 1596-56-1
Purity:  99.50%
Synonyms: NASTRp
Research Areas:  

Cancer

Naphthol AS-MX phosphate (NASTRp) is a small molecule inhibitor of the CREB (cyclic adenosine phosphate reaction element binding protein)-CBP (CREB binding protein) transcription factor complex. Naphthol AS-MX phosphate shows antitumor activity against lung cancer cells, inhibiting tumor cell proliferation (IC50=3.701 μmol/L), colony formation, and anchored independent growth in soft AGAR. Naphthol AS-MX phosphate can be used in the study of KRAS mutated lung cancer, especially for KRAS mutated lung cancer with poor chemotherapy resistance and prognosis .
loading...
    loading...